Literature DB >> 26968791

Clinical and Genetic Determinants of Cardiomyopathy Risk among Hematopoietic Cell Transplantation Survivors.

Kasey J Leger1, Kara Cushing-Haugen2, John A Hansen3, Wenhong Fan2, Wendy M Leisenring4, Paul J Martin3, Lue Ping Zhao2, Eric J Chow5.   

Abstract

Cardiomyopathy has been recognized as a complication after hematopoietic cell transplantation (HCT). Using a nested case-cohort design, we examined the relationships between demographic, therapeutic, and selected cardiovascular disease risk factors among ≥1-year HCT survivors who developed cardiomyopathy before (n = 43) or after (n = 89) 1 year from HCT as compared to a randomly selected subcohort of survivors without cardiomyopathy (n = 444). Genomic data were available for 79 cases and 267 noncases. Clinical and genetic covariates were examined for association with the risk of early or late cardiomyopathy. Clinical risk factors associated with both early- and late-onset cardiomyopathy included anthracycline exposure ≥250 mg/m(2) and pre-existing hypertension. Among late-onset cardiomyopathy cases, the development of diabetes and ischemic heart disease further increased risk. We replicated several previously reported genetic associations among early-onset cardiomyopathy cases, including rs1786814 in CELF4, rs2232228 in HAS3, and rs17863783 in UGT1A6. None of these markers were associated with risk of late-onset cardiomyopathy. A combination of demographic, treatment, and clinical covariates predicted early-onset cardiomyopathy with reasonable accuracy (area under the curve [AUC], .76; 95% confidence interval [CI], .68 to .83), but prediction of late cardiomyopathy was poor (AUC, .59; 95% CI .53 to .67). The addition of genetic polymorphisms with marginal associations (odds ratios ≥1.3) did not enhance prediction for either early- or late-onset cardiomyopathy. Conventional cardiovascular risk factors influence the risk of both early- and late-onset cardiomyopathy in HCT survivors. Although certain genetic markers may influence the risk of early-onset disease, further work is required to validate previously reported findings and to determine how genetic information should be incorporated into clinically useful risk prediction models.
Copyright © 2016 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiomyopathy; Heart failure; Hypertension; Single nucleotide polymorphism; Survivor

Mesh:

Substances:

Year:  2016        PMID: 26968791      PMCID: PMC4977273          DOI: 10.1016/j.bbmt.2016.02.017

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  42 in total

1.  Genome-wide significance and replication of the chromosome 12p11.22 locus near the PTHLH gene for peripartum cardiomyopathy.

Authors:  Benjamin D Horne; Kismet D Rasmusson; Rami Alharethi; Deborah Budge; Kimberly D Brunisholz; Torri Metz; John F Carlquist; Jennifer J Connolly; T Flint Porter; Donald L Lappé; Joseph B Muhlestein; Robert Silver; Josef Stehlik; James J Park; Heidi T May; Tami L Bair; Jeffrey L Anderson; Dale G Renlund; Abdallah G Kfoury
Journal:  Circ Cardiovasc Genet       Date:  2011-06-10

2.  Robust variance estimation for the case-cohort design.

Authors:  W E Barlow
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

3.  Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.

Authors:  Javier G Blanco; Can-Lan Sun; Wendy Landier; Lu Chen; Diego Esparza-Duran; Wendy Leisenring; Allison Mays; Debra L Friedman; Jill P Ginsberg; Melissa M Hudson; Joseph P Neglia; Kevin C Oeffinger; A Kim Ritchey; Doojduen Villaluna; Mary V Relling; Smita Bhatia
Journal:  J Clin Oncol       Date:  2011-11-28       Impact factor: 44.544

4.  A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy.

Authors:  Benjamin Meder; Frank Rühle; Tanja Weis; Georg Homuth; Andreas Keller; Jennifer Franke; Barbara Peil; Justo Lorenzo Bermejo; Karen Frese; Andreas Huge; Anika Witten; Britta Vogel; Jan Haas; Uwe Völker; Florian Ernst; Alexander Teumer; Philipp Ehlermann; Christian Zugck; Frauke Friedrichs; Heyo Kroemer; Marcus Dörr; Wolfgang Hoffmann; Bernhard Maisch; Sabine Pankuweit; Volker Ruppert; Thomas Scheffold; Uwe Kühl; Hans-Peter Schultheiss; Reinhold Kreutz; Georg Ertl; Christiane Angermann; Philippe Charron; Eric Villard; Françoise Gary; Richard Isnard; Michel Komajda; Matthias Lutz; Thomas Meitinger; Moritz F Sinner; H-Erich Wichmann; Michael Krawczak; Boris Ivandic; Dieter Weichenhan; Goetz Gelbrich; Nour-Eddine El-Mokhtari; Stefan Schreiber; Stephan B Felix; Gerd Hasenfuß; Arne Pfeufer; Norbert Hübner; Stefan Kääb; Eloisa Arbustini; Wolfgang Rottbauer; Norbert Frey; Monika Stoll; Hugo A Katus
Journal:  Eur Heart J       Date:  2013-07-12       Impact factor: 29.983

5.  Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.

Authors:  Henk Visscher; Colin J D Ross; S Rod Rassekh; Amina Barhdadi; Marie-Pierre Dubé; Hesham Al-Saloos; George S Sandor; Huib N Caron; Elvira C van Dalen; Leontien C Kremer; Helena J van der Pal; Andrew M K Brown; Paul C Rogers; Michael S Phillips; Michael J Rieder; Bruce C Carleton; Michael R Hayden
Journal:  J Clin Oncol       Date:  2011-09-06       Impact factor: 44.544

6.  Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood.

Authors:  Vladan Rajić; Richard Aplenc; Marusa Debeljak; Veronika Velensek Prestor; Natasa Karas-Kuzelicki; Irena Mlinaric-Rascan; Janez Jazbec
Journal:  Leuk Lymphoma       Date:  2009-10

7.  Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells.

Authors:  Swati Nagar; Jeffrey J Zalatoris; Rebecca L Blanchard
Journal:  Pharmacogenetics       Date:  2004-08

8.  Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation.

Authors:  Paul J Martin; George W Counts; Frederick R Appelbaum; Stephanie J Lee; Jean E Sanders; H Joachim Deeg; Mary E D Flowers; Karen L Syrjala; John A Hansen; Rainer F Storb; Barry E Storer
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

Review 9.  Cardiovascular disease in survivors of hematopoietic cell transplantation.

Authors:  Saro H Armenian; Eric J Chow
Journal:  Cancer       Date:  2013-10-25       Impact factor: 6.860

10.  Facile and definitive determination of human adriamycin and daunoribicin metabolites by high-pressure liquid chromatography.

Authors:  P A Andrews; D E Brenner; F T Chou; H Kubo; N R Bachur
Journal:  Drug Metab Dispos       Date:  1980 May-Jun       Impact factor: 3.922

View more
  11 in total

1.  Long-term systolic function in children and young adults after hematopoietic stem cell transplant.

Authors:  S J Rotz; C E Dandoy; M D Taylor; S Jodele; J L Jefferies; A Lane; J A El-Bietar; A W Powell; S M Davies; T D Ryan
Journal:  Bone Marrow Transplant       Date:  2017-07-17       Impact factor: 5.483

2.  Pharmacogenomics meets precision cardio-oncology: is there synergistic potential?

Authors:  Jennifer K Hockings; Jessica A Castrillon; Feixiong Cheng
Journal:  Hum Mol Genet       Date:  2020-10-20       Impact factor: 6.150

3.  Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment.

Authors:  Eric J Chow; Kasey J Leger; Neel S Bhatt; Daniel A Mulrooney; Colin J Ross; Sanjeev Aggarwal; Neha Bansal; Matthew J Ehrhardt; Saro H Armenian; Jessica M Scott; Borah Hong
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

Review 4.  Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention.

Authors:  Saro H Armenian; Gregory T Armstrong; Gregory Aune; Eric J Chow; Matthew J Ehrhardt; Bonnie Ky; Javid Moslehi; Daniel A Mulrooney; Paul C Nathan; Thomas D Ryan; Helena J van der Pal; Elvira C van Dalen; Leontien C M Kremer
Journal:  J Clin Oncol       Date:  2018-06-06       Impact factor: 44.544

Review 5.  Sex-Specific Cardiovascular Risks of Cancer and Its Therapies.

Authors:  Nicholas S Wilcox; Seth J Rotz; McKay Mullen; Evelyn J Song; Betty Ky Hamilton; Javid Moslehi; Saro H Armenian; Joseph C Wu; June-Wha Rhee; Bonnie Ky
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 17.367

6.  Prediction of cardiovascular disease among hematopoietic cell transplantation survivors.

Authors:  Saro H Armenian; Dongyun Yang; Jennifer Berano Teh; Liezl C Atencio; Alicia Gonzales; F Lennie Wong; Wendy M Leisenring; Stephen J Forman; Ryotaro Nakamura; Eric J Chow
Journal:  Blood Adv       Date:  2018-07-24

Review 7.  hiPSCs in cardio-oncology: deciphering the genomics.

Authors:  Emily A Pinheiro; K Ashley Fetterman; Paul W Burridge
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

Review 8.  Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation.

Authors:  Seth J Rotz; Thomas D Ryan; Salim S Hayek
Journal:  J Thromb Thrombolysis       Date:  2020-11-24       Impact factor: 2.300

9.  Genetics of Anthracycline Cardiomyopathy in Cancer Survivors: JACC: CardioOncology State-of-the-Art Review.

Authors:  Smita Bhatia
Journal:  JACC CardioOncol       Date:  2020-12-22

Review 10.  Regulated cell death pathways in doxorubicin-induced cardiotoxicity.

Authors:  Effimia Christidi; Liam R Brunham
Journal:  Cell Death Dis       Date:  2021-04-01       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.